T1	tradename 17 25	Kadcyla_
T2	tradename 168 175	KADCYLA
T3	tradename 238 255	KADCYLA. KADCYLA
T4	nanoparticle 257 283	ado-trastuzumab emtansine)
T5	routeofadministration 303 314	intravenous
T6	fdaapprovaldate 345 349	2013
T7	tradename 789 796	KADCYLA
T8	chemoclass 802 815	HER2-targeted
T9	chemoclass 829 850	microtubule inhibitor
T10	indication 926 965	HER2-positive, metastatic breast cancer
T11	routeofadministration 1339 1350	intravenous
T12	routeofadministration 1390 1401	intravenous
T13	tradename 1492 1499	KADCYLA
T14	dose 1503 1512	3.6 mg/kg
T15	routeofadministration 1526 1537	intravenous
T16	frequency 1547 1560	every 3 weeks
T17	frequency 1562 1575	21-day cycle)
T18	tradename 1646 1653	KADCYLA
T19	dose 1676 1686	3.6 mg/kg.
T20	tradename 1705 1712	KADCYLA
T21	adversereaction 1784 1902	infusion-related reactions, hepatotoxicity, left ventricular cardiac dysfunction, thrombocytopenia, pulmonary toxicity
T22	adversereaction 1906 1928	peripheral neuropathy)
T23	tradename 2019 2027	KADCYLA.
T24	adversereaction 2390 2409	Pulmonary Toxicity:
T25	tradename 2434 2441	KADCYLA
T26	adversereaction 2532 2587	Infusion-Related Reactions, Hypersensitivity Reactions:
T27	adversereaction 2662 2688	infusion-related reactions
T28	adversereaction 2692 2718	hypersensitivity reactions
T29	tradename 2828 2835	KADCYLA
T30	adversereaction 2857 2883	infusion-related reaction.
T31	adversereaction 2910 2921	Hemorrhage:
T32	adversereaction 2937 2947	hemorrhage
T33	adversereaction 3268 3285	Thrombocytopenia:
T34	tradename 3324 3331	KADCYLA
T35	adversereaction 3404 3418	Neurotoxicity:
T36	adversereaction 3505 3540	Grade 3 or 4 peripheral neuropathy.
T37	tradename 3811 3818	KADCYLA
T38	adversereaction 3849 3965	fatigue, nausea, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, increased transaminases, constipation
T39	adversereaction 3970 3980	epistaxis.
T40	company 4035 4044	Genentech
T41	tradename 4261 4268	KADCYLA
T42	tradename 4816 4823	KADCYLA
T43	adversereaction 4865 4894	Hepatotoxicity, liver failure
T44	adversereaction 4899 4904	death
T45	tradename 4922 4937	KADCYLA-treated
T46	tradename 5111 5118	KADCYLA
T47	adversereaction 5131 5187	reductions in left ventricular ejection fraction (LVEF).
T48	adversereaction 5673 5687	Hepatotoxicity
T49	adversereaction 5697 5725	Left Ventricular Dysfunction
T50	adversereaction 5730 5751	Embryo-Fetal Toxicity
T51	adversereaction 5756 5774	Pulmonary Toxicity
T52	adversereaction 5779 5833	Infusion Related Reactions, Hypersensitivity Reactions
T53	adversereaction 5838 5848	Hemorrhage
T54	adversereaction 5853 5869	Thrombocytopenia
T55	adversereaction 5874 5887	Neurotoxicity
T56	indication 6613 6637	Metastatic Breast Cancer
T57	tradename 6864 6871	KADCYLA
T58	indication 6940 6979	HER2-positive, metastatic breast cancer
T59	tradename 7338 7345	KADCYLA
T60	dose 7349 7358	3.6 mg/kg
T61	routeofadministration 7371 7382	intravenous
T62	frequency 7392 7405	every 3 weeks
T63	frequency 7407 7420	21-day cycle)
T64	tradename 7491 7498	KADCYLA
T65	dose 7521 7531	3.6 mg/kg.
T66	tradename 7551 7558	KADCYLA
T67	tradename 8182 8189	KADCYLA
T68	tradename 8469 8476	KADCYLA
T69	adversereaction 8512 8567	HEPATOTOXICITY, CARDIAC TOXICITY, EMBRYO-FETAL TOXICITY
T70	adversereaction 8580 8620	Hepatotoxicity: Serious hepatotoxicity
T71	adversereaction 8650 8663	liver failure
T72	adversereaction 8669 8674	death
T73	tradename 8700 8708	KADCYLA.
T74	tradename 8774 8781	KADCYLA
T75	tradename 8810 8817	KADCYLA
T76	tradename 8851 8858	KADCYLA
T77	adversereaction 8957 8974	Cardiac Toxicity:
T78	tradename 8976 8983	KADCYLA
T79	adversereaction 9011 9067	reductions in left ventricular ejection fraction (LVEF).
T80	tradename 9155 9163	KADCYLA.
T81	adversereaction 9271 9293	Embryo-Fetal Toxicity:
T82	tradename 9307 9314	KADCYLA
T83	adversereaction 9329 9347	embryo-fetal death
T84	adversereaction 9351 9365	birth defects.
T85	tradename 9624 9631	KADCYLA
T86	adversereaction 9691 9717	infusion-related reaction.
T87	tradename 9743 9750	KADCYLA
T88	adversereaction 9772 9798	infusion-related reactions
T89	adversereaction 9853 9970	increased serum transaminases, hyperbilirubinemia, left ventricular dysfunction, thrombocytopenia, pulmonary toxicity
T90	adversereaction 9974 9995	peripheral neuropathy
T91	tradename 10079 10086	KADCYLA
T92	dose 10249 10258	3.6 mg/kg
T93	dose 10280 10287	3 mg/kg
T94	dose 10310 10319	2.4 mg/kg
T95	adversereaction 10383 10397	Hepatotoxicity
T96	tradename 10462 10469	KADCYLA
T97	adversereaction 10500 10514	hepatotoxicity
T98	adversereaction 10528 10560	increases in serum transaminases
T99	adversereaction 10568 10586	hyperbilirubinemia
T100	adversereaction 10650 10689	Increased Serum Transaminases (AST/ALT)
T101	tradename 10915 10922	KADCYLA
T102	tradename 11024 11032	KADCYLA.
T103	adversereaction 11163 11181	Hyperbilirubinemia
T104	tradename 11311 11318	KADCYLA
T105	tradename 11425 11432	KADCYLA
T106	tradename 11543 11551	KADCYLA.
T107	tradename 11578 11585	KADCYLA
T108	tradename 11717 11724	KADCYLA
T109	tradename 12144 12151	KADCYLA
T110	tradename 12173 12181	KADCYLA.
T111	tradename 12266 12274	KADCYLA.
T112	tradename 12295 12303	KADCYLA.
T113	tradename 12422 12430	KADCYLA.
T114	tradename 12456 12464	KADCYLA.
T115	tradename 12530 12538	KADCYLA.
T116	tradename 12938 12945	KADCYLA
T117	tradename 13073 13080	KADCYLA
T118	tradename 13262 13269	KADCYLA
T119	tradename 13440 13447	KADCYLA
T120	tradename 13755 13762	KADCYLA
T121	nanoparticle 13764 13790	ado-trastuzumab emtansine)
T122	tradename 13860 13867	KADCYLA
T123	routeofadministration 13874 13885	intravenous
T124	routeofadministration 13992 14003	intravenous
T125	tradename 14042 14050	KADCYLA,
T126	tradename 14583 14590	KADCYLA
T127	tradename 14652 14659	KADCYLA
T128	tradename 15306 15313	KADCYLA
T129	tradename 15412 15419	KADCYLA
T130	tradename 15597 15604	KADCYLA
T131	tradename 15705 15712	KADCYLA
T132	tradename 15995 16002	KADCYLA
T133	nanoparticle 16395 16421	ado-trastuzumab emtansine.
T134	tradename 16668 16675	KADCYLA
T135	tradename 16904 16912	KADCYLA.
T136	tradename 17117 17124	KADCYLA
T137	tradename 17153 17160	KADCYLA
T138	tradename 17324 17331	KADCYLA
T139	tradename 17476 17483	KADCYLA
T140	tradename 17591 17598	KADCYLA
T141	tradename 17762 17770	KADCYLA,
T142	tradename 18565 18572	KADCYLA
T143	adversereaction 18622 18650	Left Ventricular Dysfunction
T144	tradename 18673 18680	KADCYLA
T145	adversereaction 18717 18746	left ventricular dysfunction.
T146	tradename 18822 18830	KADCYLA.
T147	tradename 18932 18947	KADCYLA-treated
T148	tradename 19091 19098	KADCYLA
T149	tradename 19245 19252	KADCYLA
T150	tradename 19481 19488	KADCYLA
T151	tradename 19571 19578	KADCYLA
T152	adversereaction 19905 19926	Embryo-Fetal Toxicity
T153	tradename 19928 19935	KADCYLA
T154	tradename 20050 20057	KADCYLA
T155	nanoparticle 20158 20184	ado-trastuzumab emtansine.
T156	tradename 20253 20261	KADCYLA,
T157	activeingredient 20433 20437	DM1,
T158	tradename 20465 20473	KADCYLA,
T159	adversereaction 20499 20520	embryo-fetal toxicity
T160	tradename 20569 20576	KADCYLA
T161	tradename 20654 20661	KADCYLA
T162	tradename 20708 20716	KADCYLA,
T163	tradename 20866 20874	KADCYLA.
T164	adversereaction 20908 20926	embryo-fetal death
T165	adversereaction 20931 20944	birth defects
T166	tradename 21112 21119	KADCYLA
T167	tradename 21202 21209	KADCYLA
T168	tradename 21256 21264	KADCYLA,
T169	adversereaction 21560 21578	Pulmonary Toxicity
T170	adversereaction 21588 21620	interstitial lung disease (ILD),
T171	adversereaction 21631 21643	pneumonitis,
T172	adversereaction 21660 21695	acute respiratory distress syndrome
T173	tradename 21756 21764	KADCYLA.
T174	adversereaction 21766 21777	Pneumonitis
T175	adversereaction 21870 21890	grade 3 pneumonitis.
T176	adversereaction 21919 21943	dyspnea, cough, fatigue,
T177	adversereaction 21948 21970	pulmonary infiltrates.
T178	adversereaction 22102 22113	pneumonitis
T179	tradename 22194 22201	KADCYLA
T180	adversereaction 22229 22232	ILD
T181	adversereaction 22236 22248	pneumonitis.
T182	adversereaction 22371 22390	pulmonary toxicity.
T183	tradename 22466 22473	KADCYLA
T184	tradename 22632 22639	KADCYLA
T185	adversereaction 22680 22707	Infusion-related reactions,
T186	adversereaction 22765 22837	flushing, chills, pyrexia, dyspnea, hypotension, wheezing, bronchospasm,
T187	adversereaction 22842 22853	tachycardia
T188	tradename 22895 22903	KADCYLA.
T189	tradename 22995 23002	KADCYLA
T190	tradename 23165 23172	KADCYLA
T191	tradename 23235 23242	KADCYLA
T192	tradename 23575 23583	KADCYLA.
T193	adversereaction 23698 23708	Hemorrhage
T194	tradename 23861 23869	Kadcyla.
T195	tradename 24016 24031	KADCYLA-treated
T196	tradename 24169 24184	KADCYLA-treated
T197	adversereaction 24599 24633	Thrombocytopenia Thrombocytopenia,
T198	adversereaction 24637 24662	decreased platelet count,
T199	tradename 24698 24705	KADCYLA
T200	tradename 25041 25049	KADCYLA,
T201	adversereaction 25192 25208	thrombocytopenia
T202	tradename 25226 25241	KADCYLA-treated
T203	adversereaction 25372 25388	thrombocytopenia
T204	tradename 25406 25421	KADCYLA-treated
T205	adversereaction 25537 25553	thrombocytopenia
T206	tradename 25571 25586	KADCYLA-treated
T207	tradename 25700 25707	KADCYLA
T208	tradename 25726 25733	KADCYLA
T209	tradename 25779 25786	KADCYLA
T210	tradename 25991 25998	KADCYLA
T211	adversereaction 26116 26132	thrombocytopenia
T212	co-administereddrug 26168 26182	anti-coagulant
T213	tradename 26243 26251	KADCYLA.
T214	adversereaction 26259 26295	Neurotoxicity Peripheral neuropathy,
T215	tradename 26376 26383	KADCYLA
T216	adversereaction 26541 26562	peripheral neuropathy
T217	tradename 26580 26595	KADCYLA-treated
T218	tradename 26765 26780	KADCYLA-treated
T219	tradename 26848 26855	KADCYLA
T220	adversereaction 26929 26950	peripheral neuropathy
T221	adversereaction 27075 27088	neurotoxicity
T222	tradename 27263 27270	KADCYLA
T223	company 27552 27556	Dako
T224	company 27650 27654	Dako
T225	tradename 28220 28227	KADCYLA
T226	adversereaction 28407 28451	erythema, tenderness, skin irritation, pain,
T227	adversereaction 28455 28485	swelling at the infusion site.
T228	tradename 28510 28517	KADCYLA
T229	adversereaction 28786 28800	Hepatotoxicity
T230	adversereaction 28847 28875	Left Ventricular Dysfunction
T231	adversereaction 28923 28944	Embryo-Fetal Toxicity
T232	adversereaction 28991 29009	Pulmonary Toxicity
T233	adversereaction 29056 29110	Infusion-Related Reactions, Hypersensitivity Reactions
T234	adversereaction 29158 29168	Hemorrhage
T235	adversereaction 29215 29231	Thrombocytopenia
T236	adversereaction 29279 29292	Neurotoxicity
T237	tradename 29651 29658	KADCYLA
T238	indication 29715 29754	HER2-positive metastatic breast cancer.
T239	tradename 29861 29868	KADCYLA
T240	adversereaction 29874 29990	fatigue, nausea, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, increased transaminases, constipation
T241	adversereaction 29995 30005	epistaxis.
T242	indication 30070 30108	HER2-positive metastatic breast cancer
T243	tradename 30217 30224	KADCYLA
T244	tradename 30332 30347	KADCYLA-treated
T245	tradename 30543 30558	KADCYLA-treated
T246	tradename 30672 30679	KADCYLA
T247	tradename 30775 30782	KADCYLA
T248	tradename 30991 30998	KADCYLA
T249	adversereaction 31015 31031	thrombocytopenia
T250	adversereaction 31036 31060	increased transaminases.
T251	tradename 31099 31106	KADCYLA
T252	tradename 31217 31224	KADCYLA
T253	adversereaction 31263 31305	thrombocytopenia, increased transaminases,
T254	adversereaction 31310 31332	peripheral neuropathy.
T255	tradename 31400 31407	KADCYLA
T256	tradename 31498 31505	KADCYLA
T257	adversereaction 31540 31615	neutropenia, thrombocytopenia, leukopenia, fatigue, increased transaminases
T258	adversereaction 31620 31628	pyrexia.
T259	tradename 31688 31703	KADCYLA-treated
T260	tradename 31842 31849	KADCYLA
T261	adversereaction 31900 32003	nausea, fatigue, musculoskeletal pain, hemorrhage, thrombocytopenia, increased transaminases, headache,
T262	adversereaction 32008 32021	constipation.
T263	adversereaction 32107 32192	thrombocytopenia, increased transaminases, anemia, hypokalemia, peripheral neuropathy
T264	adversereaction 32197 32205	fatigue.
T265	tradename 32278 32285	KADCYLA
T266	tradename 32389 32396	KADCYLA
T267	dose 32398 32408	3.6 mg/kg)
T268	dose 32445 32453	1250 mg)
T269	dose 32470 32482	2000 mg/m2)
T270	adversereaction 32612 32623	Neutropenia
T271	adversereaction 32640 32646	Anemia
T272	adversereaction 32665 32681	Thrombocytopenia
T273	adversereaction 32718 32746	Left ventricular dysfunction
T274	adversereaction 32777 32798	Lacrimation increased
T275	adversereaction 32811 32818	Dry eye
T276	adversereaction 32831 32845	Vision blurred
T277	adversereaction 32858 32872	Conjunctivitis
T278	adversereaction 32912 32921	Dyspepsia
T279	adversereaction 32937 32947	Stomatitis
T280	adversereaction 32966 32975	Dry Mouth
T281	adversereaction 32991 33005	Abdominal pain
T282	adversereaction 33024 33032	Vomiting
T283	adversereaction 33051 33059	Diarrhea
T284	adversereaction 33079 33091	Constipation
T285	adversereaction 33108 33114	Nausea
T286	adversereaction 33171 33187	Peripheral edema
T287	adversereaction 33202 33208	Chills
T288	adversereaction 33221 33228	Pyrexia
T289	adversereaction 33246 33254	Asthenia
T290	adversereaction 33273 33280	Fatigue
T291	adversereaction 33324 33357	Nodular regenerative hyperplasia*
T292	tradename 33433 33440	KADCYLA
T293	dose 33442 33452	3.6 mg/kg)
T294	dose 33489 33497	1250 mg)
T295	dose 33514 33526	2000 mg/m2)
T296	adversereaction 33675 33696	Drug hypersensitivity
T297	adversereaction 33744 33769	Infusion-related reaction
T298	adversereaction 33810 33833	Urinary tract infection
T299	adversereaction 33863 33899	Blood alkaline phosphatase increased
T300	adversereaction 33918 33941	Increased transaminases
T301	adversereaction 33997 34008	Hypokalemia
T302	adversereaction 34075 34082	Myalgia
T303	adversereaction 34098 34108	Arthralgia
T304	adversereaction 34124 34144	Musculoskeletal pain
T305	adversereaction 34188 34197	Dysgeusia
T306	adversereaction 34213 34222	Dizziness
T307	adversereaction 34241 34262	Peripheral neuropathy
T308	adversereaction 34282 34290	Headache
T309	adversereaction 34331 34339	Insomnia
T310	adversereaction 34407 34418	Pneumonitis
T311	adversereaction 34429 34436	Dyspnea
T312	adversereaction 34454 34459	Cough
T313	adversereaction 34478 34487	Epistaxis
T314	adversereaction 34543 34551	Pruritus
T315	adversereaction 34566 34570	Rash
T316	adversereaction 34606 34616	Hemorrhage
T317	adversereaction 34635 34647	Hypertension
T318	tradename 34842 34849	KADCYLA
T319	dose 34851 34861	3.6 mg/kg)
T320	dose 34874 34882	1250 mg)
T321	dose 34899 34910	2000 mg/m2)
T322	indication 34981 35019	HER2-positive metastatic breast cancer
T323	tradename 35052 35059	KADCYLA
T324	tradename 35183 35191	KADCYLA.
T325	tradename 35327 35335	KADCYLA.
T326	tradename 35347 35354	KADCYLA
T327	tradename 35414 35421	KADCYLA
T328	tradename 35488 35495	KADCYLA
T329	tradename 35601 35608	KADCYLA
T330	tradename 35694 35701	KADCYLA
T331	tradename 35768 35775	KADCYLA
T332	tradename 36210 36217	KADCYLA
T333	tradename 36319 36326	KADCYLA
T334	tradename 36422 36429	KADCYLA
T335	activeingredient 36483 36487	DM1,
T336	tradename 36515 36523	KADCYLA,
T337	tradename 36794 36801	KADCYLA
T338	activeingredient 36860 36863	DM1
T339	tradename 37051 37058	KADCYLA
T340	tradename 37264 37271	KADCYLA
T341	tradename 37492 37499	KADCYLA
T342	tradename 37614 37621	KADCYLA
T343	nanoparticle 37720 37746	ado-trastuzumab emtansine.
T344	tradename 37779 37786	KADCYLA
T345	activeingredient 37804 37808	DM1)
T346	tradename 37904 37911	KADCYLA
T347	tradename 37995 38002	KADCYLA
T348	tradename 38049 38057	KADCYLA,
T349	tradename 38197 38204	KADCYLA
T350	tradename 38249 38257	KADCYLA.
T351	tradename 38261 38268	KADCYLA
T352	tradename 38351 38358	KADCYLA
T353	tradename 38405 38413	KADCYLA,
T354	company 38449 38458	Genentech
T355	nanoparticle 39358 39384	ado-trastuzumab emtansine.
T356	activeingredient 39386 39390	DM1,
T357	tradename 39418 39426	KADCYLA,
T358	activeingredient 39459 39462	DM1
T359	dose 39685 39693	25 mg/kg
T360	tradename 40074 40082	KADCYLA,
T361	dose 40324 40332	25 mg/kg
T362	tradename 40369 40377	KADCYLA)
T363	tradename 40509 40517	KADCYLA,
T364	tradename 40590 40598	KADCYLA,
T365	tradename 40758 40765	KADCYLA
T366	tradename 40873 40880	KADCYLA
T367	nanoparticle 41402 41427	ado-trastuzumab emtansine
T368	tradename 41502 41509	KADCYLA
T369	adversereaction 41520 41537	embryo-fetal harm
T370	tradename 41726 41733	KADCYLA
T371	tradename 41778 41785	KADCYLA
T372	tradename 41830 41837	KADCYLA
T373	tradename 41922 41929	KADCYLA
T374	tradename 41976 41984	KADCYLA,
T375	company 42020 42029	Genentech
T376	tradename 42341 42348	KADCYLA
T377	tradename 42521 42528	KADCYLA
T378	activeingredient 42931 42934	DM1
T379	nanoparticle 43027 43052	ado-trastuzumab emtansine
T380	tradename 43146 43154	KADCYLA.
T381	tradename 43188 43195	KADCYLA
T382	tradename 43397 43404	KADCYLA
T383	dose 43408 43415	6 mg/kg
T384	tradename 43517 43524	KADCYLA
T385	tradename 43563 43570	KADCYLA
T386	nanoparticle 43572 43598	ado-trastuzumab emtansine)
T387	chemoclass 43604 43617	HER2-targeted
T388	nanoparticle 43618 43647	antibody-drug conjugate (ADC)
T389	corecomposition 43663 43701	humanized anti-HER2 IgG1, trastuzumab,
T390	chemoclass 43727 43749	microtubule inhibitory
T391	activeingredient 43755 43784	DM1 (a maytansine derivative)
T392	surfacecoating 43800 43871	thioether linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate).
T393	activeingredient 43903 43904	1
T394	corecomposition 43939 43951	trastuzumab,
T395	activeingredient 44104 44107	DM1
T396	nanoparticle 44153 44178	Ado-trastuzumab emtansine
T397	activeingredient 44206 44209	DM1
T398	nanoparticle 44235 44260	Ado-trastuzumab emtansine
T399	activeingredient 44335 44338	DM1
T400	activeingredient 44417 44420	DM1
T401	tradename 44464 44471	KADCYLA
T402	nanoparticle 44473 44499	ado-trastuzumab emtansine)
T403	nanoparticle 44628 44654	ado-trastuzumab emtansine.
T404	nanoparticle 44712 44737	ado-trastuzumab emtansine
T405	inactiveingredient 44750 44764	polysorbate 20
T406	inactiveingredient 44780 44796	sodium succinate
T407	inactiveingredient 44810 44817	sucrose
T408	nanoparticle 44917 44942	ado-trastuzumab emtansine
T409	routeofadministration 44962 44973	intravenous
T410	nanoparticle 45055 45080	Ado-trastuzumab emtansine
T411	chemoclass 45086 45099	HER2-targeted
T412	nanoparticle 45100 45124	antibody-drug conjugate.
T413	corecomposition 45146 45184	humanized anti-HER2 IgG1, trastuzumab.
T414	activeingredient 45216 45220	DM1,
T415	chemoclass 45226 45248	microtubule inhibitor.
T416	nanoparticle 45302 45327	ado-trastuzumab emtansine
T417	activeingredient 45448 45452	DM1-
T418	activeingredient 45498 45501	DM1
T419	nanoparticle 45688 45713	ado-trastuzumab emtansine
T420	tradename 45957 45964	KADCYLA
T421	nanoparticle 46051 46076	ado-trastuzumab emtansine
T422	activeingredient 46406 46409	DM1
T423	tradename 46457 46464	KADCYLA
T424	activeingredient 46553 46556	DM1
T425	activeingredient 46631 46634	DM1
T426	tradename 46658 46665	KADCYLA
T427	cmax 46685 46701	83.4 (16.5) g/mL
T428	cmax 46706 46724	4.61 (1.61) ng/mL,
T429	activeingredient 46771 46774	DM1
T430	activeingredient 46819 46822	DM1
T431	volumeofdistribution 46958 46965	3.13 L.
T432	activeingredient 47009 47013	DM1,
T433	tradename 47046 47054	KADCYLA,
T434	activeingredient 47090 47093	DM1
T435	nanoparticle 47169 47194	ado-trastuzumab emtansine
T436	activeingredient 47213 47215	1,
T437	activeingredient 47226 47228	1,
T438	activeingredient 47233 47236	DM1
T439	routeofadministration 47337 47348	intravenous
T440	tradename 47361 47369	KADCYLA,
T441	clearance 47399 47409	0.68 L/day
T442	eliminationhalflife 47465 47472	4 days.
T443	tradename 47493 47500	KADCYLA
T444	routeofadministration 47539 47550	intravenous
T445	frequency 47560 47574	every 3 weeks.
T446	nanoparticle 47858 47883	ado-trastuzumab emtansine
T447	nanoparticle 47952 47977	ado-trastuzumab emtansine
T448	tradename 48109 48116	KADCYLA
T449	dose 48169 48178	3.6 mg/kg
T450	nanoparticle 48991 49017	ado-trastuzumab emtansine.
T451	tradename 49083 49090	KADCYLA
T452	dose 49092 49101	3.6 mg/kg
T453	indication 49206 49245	HER2-positive metastatic breast cancer.
T454	nanoparticle 49473 49499	ado-trastuzumab emtansine.
T455	activeingredient 49511 49514	DM1
T456	activeingredient 49673 49676	DM1
T457	tradename 49709 49717	KADCYLA.
T458	activeingredient 49719 49722	DM1
T459	tradename 49847 49854	KADCYLA
T460	nanoparticle 49923 49948	ado-trastuzumab emtansine
T461	dose 50118 50127	60 mg/kg;
T462	nanoparticle 50324 50349	ado-trastuzumab emtansine
T463	frequency 50355 50372	every three weeks
T464	duration 50377 50385	12 weeks
T465	dose 50409 50417	30 mg/kg
T466	nanoparticle 50762 50787	ado-trastuzumab emtansine
T467	dose 50794 50802	30 mg/kg
T468	activeingredient 51100 51104	DM1,
T469	adversereaction 51137 51150	neurotoxicity
T470	indication 51214 51238	Metastatic Breast Cancer
T471	tradename 51255 51262	KADCYLA
T472	indication 51345 51359	HER2-positive,
T473	indication 51393 51418	metastatic breast cancer.
T474	tradename 51885 51893	KADCYLA.
T475	tradename 52167 52174	KADCYLA
T476	routeofadministration 52185 52198	intravenously
T477	dose 52202 52211	3.6 mg/kg
T478	frequency 52226 52239	21-day cycle.
T479	dose 52271 52278	1250 mg
T480	frequency 52278 52282	/day
T481	routeofadministration 52283 52289	orally
T482	frequency 52290 52302	once per day
T483	frequency 52308 52320	21-day cycle
T484	dose 52358 52368	1000 mg/m2
T485	routeofadministration 52369 52375	orally
T486	frequency 52376 52387	twice daily
T487	frequency 52406 52419	21-day cycle.
T488	tradename 52448 52455	KADCYLA
T489	tradename 52665 52673	KADCYLA,
T490	tradename 54940 54955	KADCYLA-treated
T491	tradename 55162 55177	KADCYLA-treated
T492	tradename 55505 55512	KADCYLA
T493	tradename 55815 55822	KADCYLA
T494	tradename 56017 56024	KADCYLA
T495	tradename 56138 56145	KADCYLA
T496	tradename 57392 57399	KADCYLA
T497	tradename 59081 59088	KADCYLA
T498	nanoparticle 59090 59116	ado-trastuzumab emtansine)
T499	adversereaction 59544 59563	severe liver injury
T500	adversereaction 59654 59669	acute hepatitis
T501	adversereaction 59678 59710	nausea, vomiting, abdominal pain
T502	adversereaction 59723 59742	RUQ abdominal pain)
T503	adversereaction 59744 59797	jaundice, dark urine, generalized pruritus, anorexia,
T504	adversereaction 59943 60118	new onset or worsening shortness of breath, cough, swelling of the ankles/legs, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness
T505	tradename 60232 60239	KADCYLA
T506	adversereaction 60285 60303	embryo-fetal death
T507	adversereaction 60307 60320	birth defects
T508	tradename 60460 60467	KADCYLA
T509	tradename 60512 60519	KADCYLA
T510	tradename 60612 60619	KADCYLA
T511	tradename 60658 60666	KADCYLA,
T512	tradename 60811 60818	KADCYLA
T513	tradename 60871 60878	KADCYLA
T514	tradename 60925 60933	KADCYLA,
T515	tradename 61056 61063	KADCYLA
T516	tradename 61241 61248	KADCYLA
T517	nanoparticle 61250 61276	ado-trastuzumab emtansine]
T518	company 61296 61311	Genentech, Inc.
T519	company 61328 61339	Roche Group
T520	fdaapprovaldate 61435 61448	February 2013
T521	tradename 61453 61460	KADCYLA
T522	company 61479 61494	Genentech, Inc.
